Climb Bio Inc (CLYM) Stock Forecast
CLYM analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.87 / 5 from 15 analysts
- Price target
- $27.57 average of analyst targets
- Upside to target
- +180.8% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.19
- 52-week range
- $1.64 – $17.84
CLYM analyst ratings
15 analystsNumber of analysts at each rating.
CLYM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CLYM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.19 | −$0.23 | −$0.16 | −$0.19 | −2.1% | 10 |
| Current fiscal year (2026) | −$0.78 | −$0.85 | −$0.70 | −$0.88 | +11.8% | 10 |
| Next fiscal year (2027) | −$1.00 | −$1.15 | −$0.76 | −$0.78 | −29.2% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CLYM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 15 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 15 |
| Next fiscal year (2027) | $500,000 | $0 | $7.5M | 0.0% | 15 |
CLYM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CLYM revenue: reported and forecast
CLYM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.20 | −$0.19 | −$0.19 | −$0.19 | −8.2% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.87 | −$0.78 | −$0.78 | −$0.78 | −$0.78 | −10.5% | 0 up · 0 down |
| Next fiscal year (2027) | −$1.12 | −$1.06 | −$1.00 | −$1.00 | −$1.00 | −10.6% | 2 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CLYM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CLYM beat in 4 of 9.
What analysts expect from CLYM
15 analysts cover Climb Bio; their consensus rating is strong buy (4.87 on a 1–5 scale, where 5 is a strong buy). The average price target is $27.57, 180.8% above the latest close of $9.82. Analysts expect earnings of −$0.78 per share for 2026, +11.8% from a year earlier. For 2027 the average estimate is −$1.00 per share on revenue of $0.5 million. Climb Bio beat the EPS estimate in 4 of the last 9 quarters.
Related: CLYM income statement, CLYM key metrics, CLYM chart. See the CLYM stock overview for the latest quote and news.
CLYM forecast FAQ
What is Climb Bio's price target?
The average analyst price target for Climb Bio is $27.57, 180.8% above the latest close of $9.82.
Is Climb Bio a buy, hold or sell?
Of 15 analysts covering Climb Bio, 13 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Climb Bio's EPS forecast?
Analysts forecast −$0.78 per share for 2026 (range −$0.85 to −$0.70); for 2027 the estimate is −$1.00.
When does Climb Bio report earnings?
Climb Bio is expected to report results for the quarter ending September 30, 2026 on November 5, 2026; the EPS estimate is $-0.19.
Does Climb Bio usually beat earnings estimates?
Climb Bio reported EPS at or above the analyst estimate in 4 of the last 9 quarters.